A carregar...
Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predo...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7470466/ https://ncbi.nlm.nih.gov/pubmed/32908943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa285 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|